Active Ingredient: oxytetracycline


  • Double dosage regimen
  • First choice antimicrobial with broad-spectrum activity
  • High bioavailability


Each ml contains: oxytetracycline (as oxytetracycline hydrochloride) 100 mg.


Solution for injection.


Cattle, sheep, horses, dogs, cats


Oxtra DD is a Dual Dosage 10% injectable solution of oxytetracycline with superior tolerability, high bioavailability, deep tissue and intracellular penetration, wide distribution, and a broad spectrum of activity. Oxtra DD, thanks to its special formulation, can be administered intramuscularly, every 24 hours either at a low dose rate or at a higher dose rate for a long lasting action. Differently from most injectable oxytetracyclines, Oxtra DD is also safely administrable via intravenously route. The blood plasma concentrations obtained with a Dual Dosage 10%-oxytetracycline (Prolonged action dosage regimen) in the first 12 hours after injection are significantly higher than those of a Long Acting 20%-formulation and remain more elevated for 30-36 hours. This results in quicker and higher peak concentrations and a more rapid therapeutic response, still assuring a long lasting effect when the higher dosage regimen is used.


Oxtra DD is indicated in the treatment of a wide range of infections caused by organisms susceptible to oxytetracycline, including: respiratory infections, urinary tract infections, metritis, mastitis, skin and soft tissue infections, infections of the feet, septic arthritis, infectious keratoconjunctivitis.


Cattle, sheep, horses: IM or IV use.
Dogs and cats: SC or IM use.


24 hourly dosage regimen: 3-10 mg/kg body weight depending on age and species. The treatment may be repeated at 24 hours intervals for 3 to 5 consecutive days. Prolonged action dosage regimen: 10 or 20 mg/kg body weight in cattle, sheep, depending on age and species. Intramuscular injection only, repeated once after 48-60 hours if required.


There are no reviews yet.

Be the first to review “OXTRA DD”

Your email address will not be published. Required fields are marked *